JohnLesterGoudreauDO

Neurology • East Lansing, MI

Associate Professor, Neurology/Ophthalmology, Michigan State University, College of Human Medicine

Join to view full profile

Dr. Goudreau is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Goudreau's full profile

Already have an account?

Office
804 Service Rd # A217
East Lansing, MI 48824
Phone+1 517-353-8122

Fax+1 517-432-3713
Is this information wrong?

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1997 - 2000
Michigan State University College of Osteopathic MedicineClass of 1995

Certifications & Licensure

MI State License 2001 - 2026
MN State License 1997 - 2005
FL State License 1999 - 2002
AZ State License 1996 - 1997
American Board of Psychiatry and Neurology Neurology
AOA Board of Neurology and Psychiatry Neurology

Clinical Trials

A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation Start of enrollment: 2013 Sep 01
Terminated
Phase 2
Efficacy of Isradipine in Early Parkinson Disease Start of enrollment: 2014 Nov 01
Completed
Phase 3

Publications & Presentations

PubMed

rs10501087, rs1491850 and rs11030094 polymorphisms associated with delayed progression in early-stage Parkinson's disease.
D Luke Fischer, Peggy Auinger, John L Goudreau, Katrina L Paumier, Allyson Cole-Strauss, Christopher J Kemp, Jack W Lipton, Caryl E Sortwell, Fischer, D. L.> ;Frontiers in Neurology. 2022 Jan 1
75 citations
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial
Michael A. Schwarzschild, Alberto Ascherio, Cindy Casaceli, Gary C. Curhan, Rebecca Fitzgerald, Cornelia Kamp, Codrin Lungu, Eric A. Macklin, Kenneth Marek, Dariush Mo...> ;JAMA. 2021 Sep 14
3 citations
Heterozygous VPS13A and PARK2 Mutations in a Patient with Parkinsonism and Seizures.
Steven D. Mitchell, Roger L. Albin, William T. Dauer, John L. Goudreau, Christos Sidiropoulos> ;Case Reports in Neurology. 2021 May 1
74 citations
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial.
Tanya Simuni, Brian K. Fiske, Kalpana Merchant, Christopher S. Coffey, Elizabeth A. Klingner, Chelsea Caspell-Garcia, David-Erick Lafontant, Helen Matthews, Richard K....> ;JAMA Neurology. 2021 Mar 1
10 citations
BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson’s Disease
D. Luke Fischer, Peggy Auinger, John L. Goudreau, Allyson Cole-Strauss, Karl Kieburtz, Jordan J. Elm, Mallory L. Hacker, P. David Charles, Jack W. Lipton, Barbara A. P...> ;Neurotherapeutics. 2020 Nov 19
4 citations
Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfun...
Jessica S. Fortin, Matthew J. Benskey, Keith J. Lookingland, Jon S. Patterson, Erin B. Howey, John L. Goudreau, Harold C. Schott> ;BMC Veterinary Research. 2020 Sep 25
31 citations
Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial
Michael A. Schwarzschild, Eric A. Macklin, Rachit Bakshi, Shamik Battacharyya, Robert Logan, Alberto J. Espay, Albert Y. Hung, Grace Bwala, Christopher G. Goetz, David...> ;Neurology. 2019 Oct 1
13 citations
Bdnf variant is associated with milder motor symptom severity in early-stage Parkinson's disease.
D. Luke Fischer, Peggy Auinger, John L. Goudreau, Katrina L. Paumier, Allyson Cole-Strauss, Christopher J. Kemp, Jack W. Lipton, Caryl E. Sortwell> ;Parkinsonism & Related Disorders. 2018 May 9
8 citations
Critical appraisal of the recent US FDA approval for earlier DBS intervention.
Laura Y. Cabrera, John L. Goudreau, Christos Sidiropoulos> ;Neurology. 2018 Jul 17
15 citations
Metabolism of Dopamine in Nucleus Accumbens Astrocytes Is Preserved in Aged Mice Exposed to MPTP.
Brittany M. Winner, Harue Zhang, McKenzie M. Farthing, Lalitha M. Karchalla, Keith J. Lookingland, John L. Goudreau> ;Frontiers in Aging Neuroscience. 2017 Dec 12
15 citations
Autonomic and electrocardiographic findings in Parkinson’s disease
Christopher H. Gibbons, David Simon, Meilin Huang, Barbara C. Tilley, Michael J. Aminoff, Jacquelyn L. Bainbridge, Matthew Brodsky, Roy Freeman, John L. Goudreau, Robe...> ;Autonomic Neuroscience. 2017 Jul 1
24 citations
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.
Robert A. Hauser, Ruosha Li, Adriana Pérez, Xuehan Ren, Dan Weintraub, Jordan J. Elm, John L. Goudreau, John C. Morgan, John Y. Fang, Michael J. Aminoff, Chadwick W. C...> ;Journal of Parkinson's Disease. 2017 Jan 1
6 citations
FosB and ΔFosB expression in brain regions containing differentially susceptible dopamine neurons following acute neurotoxicant exposure.
Joseph R. Patterson, Elizabeth J. Kim, John L. Goudreau, Keith J. Lookingland> ;Brain Research. 2016 Oct 15
6 citations
Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America
John L. Goudreau, Adriana Pérez, Michael J. Aminoff, James T. Boyd, Keith D. Burau, Chadwick W. Christine, Maureen A. Leehey, John C. Morgan> ;Journal of the Neurological Sciences. 2016 Jul 15
5 citations
Reduced Noradrenergic Signaling in the Spleen Capsule in the Absence of CB1 and CB2 Cannabinoid Receptors
Tyrell J. Simkins, David Fried, Kevin Parikh, James J. Galligan, John L. Goudreau, Keith J. Lookingland, Barbara L. F. Kaplan> ;Journal of Neuroimmune Pharmacology. 2016 Jun 10
9 citations
Comparison of the structure, function and autophagic maintenance of mitochondria in nigrostriatal and tuberoinfundibular dopamine neurons
Hae Young Hawong, Joseph R. Patterson, Brittany M. Winner, John L. Goudreau, Keith J. Lookingland> ;Brain Research. 2015 Oct 5
163 citations
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Tanya Simuni, Karl Kieburtz, Barbara C. Tilley, Jordan J. Elm, Bernard Ravina, Debra Babcock, Marina E. Emborg, Robert A. Hauser, Cornelia Kamp, John C. Morgan, G. Web...> ;The Lancet. Neurology. 2015 Aug 1
20 citations
Methylmercury Impairs Canonical Dopamine Metabolism in Rat Undifferentiated Pheochromocytoma (PC12) Cells by Indirect Inhibition of Aldehyde Dehydrogenase
Chelsea T. Tiernan, Ethan A. Edwin, Hae Young Hawong, Mónica Ríos-Cabanillas, John L. Goudreau, William D. Atchison, Keith J. Lookingland> ;Toxicological Sciences. 2015 Apr 1
68 citations
GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.
Joel J. Credle, J. L. George, J. Wills, Valeriy Duka, K. Shah, Y. C. Lee, Olga Rodriguez, Tyrell J. Simkins, M. Winter, D. Moechars, T. Steckler, John L. Goudreau, Dav...> ;Cell Death and Differentiation. 2015 Apr 1
5 citations
Parkinson's disease severity and use of dopaminergic medications
John Y. Fang, Adriana Pérez, Chadwick W. Christine, Maureen A. Leehey, Michael J. Aminoff, James T. Boyd, John C. Morgan, Rohit Dhall, Anthony P. Nicholas, Ivan Bodis-...> ;Parkinsonism & Related Disorders. 2015 Mar 1
5 citations
The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure
Matthew J. Benskey, Fredric P. Manfredsson, Keith J. Lookingland, John L. Goudreau> ;Neurotoxicology. 2015 Jan 1
6 citations
Enhanced Humoral Immunity in Mice Lacking CB1 and CB2 Receptors ( Cnr1 −/− /Cnr2 −/− Mice) is not Due to Increased Splenic Noradrenergic Neuronal Activity
Tyrell J. Simkins, Robert B. Crawford, John L. Goudreau, Keith J. Lookingland, Barbara L. F. Kaplan> ;Journal of Neuroimmune Pharmacology. 2014 May 29
180 citations
Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease: A Randomized Clinical Trial
Michael A. Schwarzschild, Alberto Ascherio, M. Flint Beal, Merit Cudkowicz, Gary C. Curhan, Joshua M. Hare, D. Craig Hooper, Karl Kieburtz, Eric A. Macklin, David Oake...> ;JAMA Neurology. 2014 Feb 1
16 citations
Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of par...
Matthew J. Benskey, Ki Yong Lee, Kevin Parikh, Keith J. Lookingland, John L. Goudreau> ;Neurotoxicology. 2013 Jul 1
8 citations
The role of de novo catecholamine synthesis in mediating methylmercury-induced vesicular dopamine release from rat pheochromocytoma (PC12) cells
Chelsea T. Tiernan, Ethan A. Edwin, John L. Goudreau, William D. Atchison, Keith J. Lookingland> ;Toxicological Sciences. 2013 May 1
Join now to see all

Grant Support

The Role Of Parkin In Selective Dopamine Neuronal DegenerationNational Institute Of Neurological Disorders And Stroke2010–2012
Michigan State University Parkinson Disease Clinical CenterNational Institute Of Neurological Disorders And Stroke2006–2011
Neuroprotective Factors In Hypothalamic Dopamine NeuronsNational Institute Of Neurological Disorders And Stroke2005–2006
Apocynin Neuroprotection In A Parkinson'S Disease ModelNational Institute Of Neurological Disorders And Stroke2005–2006